MiniMed (Nasdaq:MMED) announced today that it expanded its agreement with Abbott (NYSE:ABT) to add more sensors to its portfolio.
The company also announced fourth-quarter earnings results in tandem with the new Abbott integration.
MiniMed has an existing partnership with Abbott through a collaboration between the companies agreed in 2024. They integrated Instinct, a sensor made by Abbott and based on the FreeStyle Libre platform, into Medtronic insulin delivery offerings.
Now, the companies plan to commercialize dual glucose-ketone sensors and integrate them with MiniMed smart dosing systems. Abbott has long touted the dual sensor that continuously measures glucose and ketone levels every minute. The sensors provide real-time visibility into glucose levels as a standard CGM like Abbott’s FreeStyle Libre system does, but also into rising ketones that can lead to a diabetic ketoacidosis (DKA) emergency.
Last week, Abbott reached a milestone with CE mark for the sensors, branded as Libre Duo and Libre Duo 10 Day. The sensors remain investigational in the U.S.
MiniMed plans to offer the sensors across its automated insulin delivery and smart multiple daily injection (MDI) systems. The sensors will be the same size as Instinct. The companies plan to provide further updates on regulatory and commercialization milestones in the coming months.
“By integrating dual glucose-ketone monitoring sensors with our MiniMed smart dosing systems, we’re adding an additional layer of intelligence and protection,” said Que Dallara, CEO. “Our system is designed to keep people in tight glucose control and minimize DKA risk through smarter, more consistent automation — intervening before it ever becomes an emergency. This partnership with Abbott takes that commitment even further. At MiniMed, our mission is to make every day a better day for people with diabetes, and that means relentlessly pursuing innovations that not only improve outcomes but also deliver genuine peace of mind.”
A look at the company’s earnings results
MiniMed today posted fourth-quarter results that topped the consensus sales forecast.
Shares of MMED ticked up 5.82% to $13.02 apiece before the market opened today.
The Northridge, California-based former Medtronic Diabetes unit reported losses of $183 million. That equals 68¢ per share on sales of $837 million for the three months ended April 24, 2026.
MiniMed recorded an 8.9% bottom-line slide on a sales increase of 15.6%. Sales landed well ahead of expectations on Wall Street, as experts forecast $788.7 million in revenue.
The company reported international sales of $599 million, growing 22.4%, with Simplera CGM expansion driving growth. U.S. sales of $238 million grew 1.5%, as FDA clearance for the new MiniMed Flex system shifted demand, with customers awaiting the new system that’s on track to launch this month. The company already began taking pre-orders for the system, while it expects CE mark ahead of potential European expansion this year.
For fiscal 2027, MiniMed expects organic revenue growth of approximately 10%. It expects an adjusted EBITDA margin of approximately 16%.
“MiniMed delivered a strong finish to our fiscal year, driven by strength in international markets and continued global adoption of the MiniMed 780G system,” said Dallara. “Looking ahead, we’re confident that our launches of MiniMed Flex and MiniMed Go will support long-term growth acceleration and value creation.”
Takeaways from the MiniMed earnings call
On the company’s earnings call today, Dallara outlined some of the plans for the company’s future portfolio. That includes the company’s Fit patch pump, which is set to challenge that area of the diabetes tech market, currently led by Insulet’s Omnipod 5 and potentially adding patches from Tandem Diabetes Care and Beta Bionics in the near future as well.
Additionally, the next-generation pipeline described as “busy” includes a next-generation algorithm. The company said earlier this year that it began a U.S. pivotal study for Vivera, its third-generation algorithm for AID. According to analysts, the Fit patch pump and Vivera algorithm should broaden MiniMed’s addressable market and sustain growth.
Today, Dallara said both Fit and Vivera remain on track for FDA clearance next year. The company expects to submit Fit to the FDA this fall, while the company began a pivotal trial for Vivera in February and said it sits at around 50% of the targeted enrollment.
Additionally, Dallara said the company already has manufacturing operations underway for the Fit pump. It expects the initial capacity to serve 20,000 patients at launch as it is “scaling capacity quickly.”
“We are in the middle of a complete portfolio transformation,” Dallara said. “Within 18 months, a person living with diabetes will be able to choose MiniMed at any stage of their journey. … One company. Every option.
“We believe this will completely reshape how the market thinks of MiniMed.”
The analysts’ take
BTIG analysts Marie Thibault, Alexandra Pang and Sam Eiber maintained a “Buy” rating for MiniMed following the results.
The analysts labeled fiscal 2027 as a “catalyst-rich year,” noting the Flex launch in the U.S., continued MiniMed Go expansion and the broader rollout of the Simplera and Instinct sensors outside the U.S.
“We think [MiniMed] is off to a strong start and see opportunities for outperformance throughout the coming fiscal year,” the analysts said.
